精彩内容近日,CDE官网显示,石药集团的达格列净二甲双胍缓释片(Ⅳ)、达格列净二甲双胍缓释片(Ⅲ)、达格列净二甲双胍缓释片(Ⅱ)、达格列净二甲双胍缓释片(Ⅰ)以仿制4类报产获受理。米内网数据显示,2025年一季度中国三大终端六大市场(统计范围详见本文末)达格列净二甲双胍销售额超过1亿元,同比增长约209%。达格列净二甲双胍是由达格列净(SGLT2抑制剂)和盐酸二甲双胍(双胍类)组成的复方制剂,适用...
Source Link精彩内容近日,CDE官网显示,石药集团的达格列净二甲双胍缓释片(Ⅳ)、达格列净二甲双胍缓释片(Ⅲ)、达格列净二甲双胍缓释片(Ⅱ)、达格列净二甲双胍缓释片(Ⅰ)以仿制4类报产获受理。米内网数据显示,2025年一季度中国三大终端六大市场(统计范围详见本文末)达格列净二甲双胍销售额超过1亿元,同比增长约209%。达格列净二甲双胍是由达格列净(SGLT2抑制剂)和盐酸二甲双胍(双胍类)组成的复方制剂,适用...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.